000157634 001__ 157634
000157634 005__ 20240229123142.0
000157634 0247_ $$2doi$$a10.1186/s13014-020-01647-8
000157634 0247_ $$2pmid$$apmid:32831113
000157634 0247_ $$2altmetric$$aaltmetric:88849170
000157634 037__ $$aDKFZ-2020-01729
000157634 041__ $$aeng
000157634 082__ $$a610
000157634 1001_ $$0P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aBostel, Tilmann$$b0$$eFirst author$$udkfz
000157634 245__ $$aHigh-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas: long-term clinical results of a single particle therapy center.
000157634 260__ $$aLondon$$bBioMed Central$$c2020
000157634 3367_ $$2DRIVER$$aarticle
000157634 3367_ $$2DataCite$$aOutput Types/Journal article
000157634 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600152720_30882
000157634 3367_ $$2BibTeX$$aARTICLE
000157634 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157634 3367_ $$00$$2EndNote$$aJournal Article
000157634 500__ $$a#EA:E050#
000157634 520__ $$aThis study aimed to analyze the oncological long-term results and late toxicity of carbon ion-based radiotherapy (RT) of patients with sacral chordoma and to identify potential prognostic factors for local control (LC) and overall survival (OS).A total of 68 patients with sacral chordoma treated at the Heidelberg Ion Beam Therapy Center were included in this study. Of these 52 patients (77%) received a primary RT and 16 patients (23%) received a RT in a recurrent situation. All patients were treated with carbon ion RT (CIRT), either in combination with photons (n = 22; 32%) or as a monotherapy (n = 46; 68%), with a median radiation dose of 66 Gy RBE (range 60-74 Gy). In 40 patients (59%), RT was performed in the postoperative situation. Postoperative care included regular MRI scans. Local progression was defined as an enlargement of the maximum tumor diameter by 10% or a new tumor growth within the planning target volume (PTV). LC and OS were determined using the Kaplan-Meier method. Furthermore, the relevance of various prognostic factors for LC and OS was assessed by univariate and multivariate analysis.The median follow-up period was 60 months (range 1.3-97.4 months). The 5-year rates for LC, progression-free survival, metastasis-free survival and OS were 53, 53, 52 and 74%, respectively. Local recurrence was observed in 31 patients (46%), occurring after a median follow-up time of 25 months (range 2.5-73.1 months). Only 10% of local recurrences occurred later than 5 years after RT. Statistical analysis showed that RT in the relapse situation corresponded to inferior LC rates compared to the primary situation, while other factors such as the GTV, radiation dose (EQD2) and treatment approach (CIRT alone vs. CIRT combined with photons) were insignificant. For OS after RT, patient age and PTV size proved to be significant predictors. The incidence of late toxicity ≥ III° according to CTCAE v5.0 was 21%. Sacral insufficiency fractures occurred in 49% of patients (maximum III°: 16%) and were thus by far the most frequent late side effect in our analysis. Radiogenic damage to the peripheral nerves, intestinal tract and skin was observed in only 9% (≥ III°: 5%), 3% (all II°) and 9% (all I°) of patients.Our analysis showed only moderate long-term LC rates after carbon ion-based RT, with sacral chordomas having a particularly poor prognosis in the recurrent situation. Therefore, future studies should evaluate the safety and effectiveness of further dose escalation and hypofractionation of RT in sacral chordoma and weight potential benefits of dose escalation against side effects.
000157634 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000157634 588__ $$aDataset connected to CrossRef, PubMed,
000157634 7001_ $$aMattke, Matthias$$b1
000157634 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils Henrik$$b2$$udkfz
000157634 7001_ $$aWelzel, Thomas$$b3
000157634 7001_ $$aWollschläger, Daniel$$b4
000157634 7001_ $$aAkbaba, Sati$$b5
000157634 7001_ $$aMayer, Arnulf$$b6
000157634 7001_ $$aSprave, Tanja$$b7
000157634 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b8$$udkfz
000157634 7001_ $$aUhl, Matthias$$b9
000157634 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-020-01647-8$$gVol. 15, no. 1, p. 206$$n1$$p206$$tRadiation oncology$$v15$$x1748-717X$$y2020
000157634 909CO $$ooai:inrepo02.dkfz.de:157634$$pVDB
000157634 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157634 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000157634 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000157634 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000157634 9141_ $$y2020
000157634 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-12
000157634 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000157634 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-12
000157634 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157634 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157634 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x1
000157634 980__ $$ajournal
000157634 980__ $$aVDB
000157634 980__ $$aI:(DE-He78)E050-20160331
000157634 980__ $$aI:(DE-He78)E055-20160331
000157634 980__ $$aUNRESTRICTED